Successful treatment of galli-galli disease with dupilumab and acitretin combination therapy: A case report

Authors

  • Matthew Reedy, MD Trillium Creek Dermatology and Surgery Center, Medina, OH, USA , Northeast Ohio Medical University, Rootstown, OH, USA Author
  • Jordan Goad, PA-C Trillium Creek Dermatology and Surgery Center, Medina, OH, USA Author
  • Joshua Weaver, MD Trillium Creek Dermatology and Surgery Center, Medina, OH, USA , Northeast Ohio Medical University, Rootstown, OH, USA Author

DOI:

https://doi.org/10.25251/2wjkzs75

Keywords:

acantholytic, dowling-degos, dupilumab, galli-galli

References

1. Gilchrist, H.; Jackson, S.; Morse, L.; Nesbitt, L.T. Galli-Galli disease: A case report with review of the literature. J. Am. Acad. Dermatol. 2008, 58, 299–302.

2. Hanneken, S.; Rütten, A.; Pasternack, S.M.; Eigelshoven, S.; El Shabrawi-Caelen, L.; et al. Systematic mutation screening of KRT5 supports the hypothesis that Galli-Galli disease is a variant of Dowling-Degos disease. Br. J. Dermatol. 2010, 163, 197–200.

3. Deenen, N.J.; Damman, J.; Nijsten, T.E.C. Galli–Galli disease successfully treated with alitretinoin. J. Eur. Acad. Dermatol. Venereol. 2019, 33, e232–e233.

4. Michelerio A, Greco A, Tomasini D, Tomasini C. Galli–Galli Disease: A Comprehensive Literature Review. Dermatopathology. 2024; 11(1):79-100. https://doi.org/10.3390/dermatopathology11010008

5. Shirley M. Dupilumab: First Global Approval. Drugs. 2017;77(10):1115-1121. doi:10.1007/s40265-017-0768-3.

6. Butler, D.C.; Kollhoff, A.; Berger, T. Treatment of Grover Disease with Dupilumab. JAMA Dermatol. 2021, 157, 353.

Downloads

Published

05/09/2026

Data Availability Statement

This manuscript has not been published and is not under consideration for publication elsewhere.

Issue

Vol. 32 No. 2 (2026): Dermatology Online Journal

Section

Case Report / Case Series

License

Copyright (c) 2026 Matthew Reedy, MD, Jordan Goad, PA-C, Joshua Weaver, MD (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.